Lysosomal Alpha Glucosidase (LAG) Market Analysis-2027

1. LYSOSOMAL ALPHA GLUCOSIDASE MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Lysosomal Alpha Glucosidase Market - Overview Lysosomal Alpha Glucosidase Market - Regional Analysis Based on geography, the Lysosomal Alpha Glucosidase Market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific and Africa. Europe is expected to be dominant market during the forecast period attributed to higher rate of incidence in these region. For instance, according to Feb 2018 published article of BMJ Paediatrics Open journal, the incidence of infantile Pompe disease in the Maroon community of France is roughly 50 times higher than elsewhere in the world. Lysosomal alpha glucosidase is a recombinant enzyme used for the treatment of lysosomal storage disorder known as Pompe disease. Pompe disease, also known as Acid Maltase Deficiency or Glycogen Storage Disease type II. Pompe disease is considered to be an inherited fatal muscular myopathy disorder caused due to glycogen build-up in the body cells such as in cardiac, smooth, and skeletal muscle cells. Pompe disease is characterized by absence or deficiency of the lysosomal enzyme alpha-glucosidase (GAA). Large number of pipeline product is the major factor driving lysosomal alpha glucosidase market. In 2016, Genzyme, a unit of Sanofi, initiated phase III clinical trial for NeoGAA, a second generation alglucosidase alfa enzyme based enzyme replacement therapy for Pompe disease. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing- insight/lysosomal-alpha-glucosidase-market-4153 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Lysosomal Alpha Glucosidase Market – Driver Increasing research activities along with the number of clinical trials and pipeline products is expected to boost the lysosomal alpha glucosidase market in near future. For instance, in 2017, Valerion Therapeutic, a clinical-stage biotechnology company specialized in the development of therapies for orphan genetic diseases, initiated phase 1/2 clinical trials for its candidate drug, VAL-1221 in patients with late-onset of Pompe disease. Moreover, JCR Pharmaceuticals Co. Ltd., evaluated its candidate genetically engineered enzyme, JR-162, a therapeutic enzyme product for Pompe disease. As on August 2017, JR-162 was in preclinical stage. JR-162 is developed by applying J-Brain Cargo, an innovative technology by the company that enables the delivery of intravenously administered drug compounds of large molecular weight such as protein to cross blood brain barrier. Further, in Feb 2018, Amicus Therapeutics, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for rare metabolic disease, is investigating ATB200/AT2221 in patients with Pompe disease and is in Phase1/2 clinical study. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/4153 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Moreover, in 2012, Oxyrane collaborated with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments. Further, Oxyrane, company involved in enzyme replacement therapies (ERTs) for the treatment of lysosomal storage diseases (LSDs), also has a pipeline product named OXY 2810 for Pompe disease. Lysosomal Alpha Glucosidase Market – Competitor The global market of lysosomal alpha glucosidase market is led by Genzyme Corp., a unit of Sanofi. The player with pipeline product includes Pharming Group N.V., Valerion Therapeutic, Audentes Therapeutics, Inc. and Oxyrane. ATB200 is recombinant human acid alpha-glucosidase enzyme co-administered with AT2221, a pharmacological chaperone. VAL-1221 combines company’s proprietary antibody-mediated delivery technology with recombinant human acid alpha-glucosidase, offering improved glycogen clearance and better patient outcomes Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4153 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved